WO2002092620A3 - Peptides and related molecules that bind to tall-1 - Google Patents
Peptides and related molecules that bind to tall-1 Download PDFInfo
- Publication number
- WO2002092620A3 WO2002092620A3 PCT/US2002/015273 US0215273W WO02092620A3 WO 2002092620 A3 WO2002092620 A3 WO 2002092620A3 US 0215273 W US0215273 W US 0215273W WO 02092620 A3 WO02092620 A3 WO 02092620A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tall
- seq
- domain
- matter
- vehicle
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
Abstract
Priority Applications (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002589503A JP4516719B2 (en) | 2001-05-11 | 2002-05-13 | Peptides binding to TALL-1 and related molecules |
DK02769739T DK1385882T3 (en) | 2001-05-11 | 2002-05-13 | Peptides and related molecules that bind to TALL-1 |
KR1020037014672A KR100902687B1 (en) | 2001-05-11 | 2002-05-13 | Tall - 1 - binding composition |
EEP200300552A EE05294B1 (en) | 2001-05-11 | 2002-05-13 | TALL-1 binding agent composition |
CA2446189A CA2446189C (en) | 2001-05-11 | 2002-05-13 | Peptides and related molecules that bind to tall-1 |
SI200230645T SI1385882T1 (en) | 2001-05-11 | 2002-05-13 | Peptides and related molecules that bind to tall-1 |
AU2002342669A AU2002342669C1 (en) | 2001-05-11 | 2002-05-13 | Peptides and related molecules that bind to TALL-1 |
SK1489-2003A SK288175B6 (en) | 2001-05-11 | 2002-05-13 | Peptides and related molecules that bind to TALL-1 |
EP02769739A EP1385882B9 (en) | 2001-05-11 | 2002-05-13 | Peptides and related molecules that bind to tall-1 |
MXPA03010210A MXPA03010210A (en) | 2001-05-11 | 2002-05-13 | Peptides and related molecules that bind to tall-1. |
HU0700125A HU229910B1 (en) | 2001-05-11 | 2002-05-13 | Peptides and related molecules that bind to tall-1 |
NZ529267A NZ529267A (en) | 2001-05-11 | 2002-05-13 | Peptides and related molecules that bind to tall-1 |
BR0209546-7A BR0209546A (en) | 2001-05-11 | 2002-05-13 | Composition of matter, DNA, expression vector, host cell, and methods for treating B-cell mediated autoimmune disease, lupus, B-cell mediated cancer, and B-cell lymphoma |
DE60222882T DE60222882T2 (en) | 2001-05-11 | 2002-05-13 | PEPTIDES AND RELATED MOLECULES BINDING AT TALL-1 |
EA200301241A EA010435B1 (en) | 2001-05-11 | 2002-05-13 | Binding to tall-1 molecules and use thereof |
IL15871902A IL158719A0 (en) | 2001-05-11 | 2002-05-13 | Peptides and related molecules that bind to tall-1 |
IL158719A IL158719A (en) | 2001-05-11 | 2003-11-02 | Tall-1 binding composition comprising an amino acid sequence, a dna encoding said composition, an expression vector comprising said dna and a host cell comprising said expression vector |
NO20034980A NO331785B1 (en) | 2001-05-11 | 2003-11-10 | TALL-1 binding compound, DNA encoding the compound, expression vector comprising DNA, host cell comprising the expression vector and use of the compound for the manufacture of drug for the treatment of disease. |
BG108349A BG66270B1 (en) | 2001-05-11 | 2003-11-12 | Compositions comprising peptides and related molecules that bind to tall-1 |
HK04101344A HK1059269A1 (en) | 2001-05-11 | 2004-02-25 | Peptides and related molecules that bind to tall-1 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29019601P | 2001-05-11 | 2001-05-11 | |
US60/290,196 | 2001-05-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002092620A2 WO2002092620A2 (en) | 2002-11-21 |
WO2002092620A3 true WO2002092620A3 (en) | 2003-08-21 |
Family
ID=23114926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/015273 WO2002092620A2 (en) | 2001-05-11 | 2002-05-13 | Peptides and related molecules that bind to tall-1 |
Country Status (30)
Country | Link |
---|---|
US (5) | US7259137B2 (en) |
EP (4) | EP1921088B1 (en) |
JP (1) | JP4516719B2 (en) |
KR (1) | KR100902687B1 (en) |
CN (3) | CN100448891C (en) |
AT (2) | ATE549354T1 (en) |
AU (1) | AU2002342669C1 (en) |
BG (1) | BG66270B1 (en) |
BR (1) | BR0209546A (en) |
CA (1) | CA2446189C (en) |
CY (1) | CY1107131T1 (en) |
CZ (1) | CZ304592B6 (en) |
DE (1) | DE60222882T2 (en) |
DK (1) | DK1385882T3 (en) |
EA (1) | EA010435B1 (en) |
EE (1) | EE05294B1 (en) |
ES (3) | ES2527471T3 (en) |
HK (3) | HK1059269A1 (en) |
HU (1) | HU229910B1 (en) |
IL (2) | IL158719A0 (en) |
MX (1) | MXPA03010210A (en) |
NO (1) | NO331785B1 (en) |
NZ (2) | NZ542878A (en) |
PL (2) | PL393317A1 (en) |
PT (1) | PT1385882E (en) |
RS (1) | RS51708B (en) |
SI (1) | SI1385882T1 (en) |
SK (1) | SK288175B6 (en) |
WO (1) | WO2002092620A2 (en) |
ZA (1) | ZA200308513B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7645861B2 (en) | 2004-09-24 | 2010-01-12 | Amgen Inc. | Modified Fc molecules |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
US9382323B2 (en) | 2009-04-02 | 2016-07-05 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
Families Citing this family (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6812327B1 (en) * | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
US8212004B2 (en) * | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
KR101287395B1 (en) * | 2000-06-16 | 2014-11-04 | 휴먼 게놈 사이언시즈, 인코포레이티드 | Antibodies that immunospecifically bind to BLyS |
US7879328B2 (en) | 2000-06-16 | 2011-02-01 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator |
US20030091565A1 (en) * | 2000-08-18 | 2003-05-15 | Beltzer James P. | Binding polypeptides and methods based thereon |
EP2261246A3 (en) | 2000-08-18 | 2011-07-13 | Human Genome Sciences, Inc. | Binding polypeptides for B-lymphocyte stimulator protein (BLyS) |
UA83458C2 (en) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf) |
ATE549354T1 (en) * | 2001-05-11 | 2012-03-15 | Amgen Inc | PEPTIDES AND ASSOCIATED TALL-1 BINDING MOLECULES |
US7112410B1 (en) | 2001-08-29 | 2006-09-26 | Human Genome Sciences, Inc. | Human tumor necrosis factor TR21 and methods based thereon |
WO2004060911A2 (en) | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
AU2004233164B2 (en) | 2003-03-28 | 2009-10-08 | Biogen Ma Inc. | Truncated BAFF receptors |
ES2537738T3 (en) | 2003-06-05 | 2015-06-11 | Genentech, Inc. | Combination therapy for B cell disorders |
US7605120B2 (en) * | 2003-10-22 | 2009-10-20 | Amgen Inc. | Antagonists of the brandykinin B1 receptor |
AU2004315198A1 (en) | 2004-01-29 | 2005-08-18 | Genentech, Inc. | Variants of the extracellular domain of BCMA and uses thereof |
WO2005124342A2 (en) * | 2004-06-21 | 2005-12-29 | Galapagos N.V. | Methods and means for treatment of osteoarthritis |
CN100378122C (en) * | 2004-12-03 | 2008-04-02 | 中国人民解放军第三军医大学 | B lymphocyte stimulus factor inhibiting peptide and its screening and preparing method |
CA2610839C (en) | 2005-06-14 | 2019-06-25 | Amgen Inc. | Self-buffering protein formulations |
US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
NZ597082A (en) | 2005-10-13 | 2013-11-29 | Human Genome Sciences Inc | Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
JP6088723B2 (en) | 2005-11-23 | 2017-03-01 | ジェネンテック, インコーポレイテッド | Compositions and methods for B cell assays. |
WO2007123765A2 (en) | 2006-03-31 | 2007-11-01 | Human Genome Sciences Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
US7981425B2 (en) | 2006-06-19 | 2011-07-19 | Amgen Inc. | Thrombopoietic compounds |
WO2008051383A2 (en) * | 2006-10-19 | 2008-05-02 | Amgen Inc. | Use of alcohol co-solvents to improve pegylation reaction yields |
EP2162540A2 (en) | 2007-05-22 | 2010-03-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
JP5570989B2 (en) * | 2007-08-31 | 2014-08-13 | アムジエン・インコーポレーテツド | Solid protein formulation |
AU2008304111B2 (en) | 2007-09-27 | 2014-04-24 | Amgen Inc. | Pharmaceutical formulations |
EP3381445B1 (en) | 2007-11-15 | 2023-10-25 | Amgen Inc. | Aqueous formulation of antibody stablised by antioxidants for parenteral administration |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
EP2396035A4 (en) * | 2009-02-12 | 2012-09-12 | Human Genome Sciences Inc | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
US8734796B2 (en) | 2009-03-20 | 2014-05-27 | Amgen Inc. | Carrier immunoglobulins |
JP5996429B2 (en) | 2009-09-03 | 2016-09-21 | ジェネンテック, インコーポレイテッド | Method for treatment, diagnosis and monitoring of rheumatoid arthritis |
SG10201408401RA (en) | 2009-09-16 | 2015-01-29 | Genentech Inc | Coiled coil and/or tether containing protein complexes and uses thereof |
CA2778105C (en) | 2009-10-23 | 2019-04-02 | Amgen Inc. | Vial adapter and system |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
MX346731B (en) | 2010-04-23 | 2017-03-30 | Genentech Inc * | Production of heteromultimeric proteins. |
KR102513760B1 (en) | 2010-06-07 | 2023-03-27 | 암젠 인크 | Drug delivery device |
CN103154032A (en) | 2010-08-13 | 2013-06-12 | 弗·哈夫曼-拉罗切有限公司 | Antibodies to IL-1beta and IL-18, for treatment of disease |
WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
WO2012040518A2 (en) | 2010-09-22 | 2012-03-29 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
AR085138A1 (en) | 2011-02-04 | 2013-09-11 | Genentech Inc | Fc VARIATIONS AND METHODS FOR PRODUCTION |
US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
JP6271254B2 (en) | 2011-02-28 | 2018-01-31 | ジェネンテック, インコーポレイテッド | Methods for predicting biological markers and responses to B cell antagonists |
AU2012236573B2 (en) | 2011-03-31 | 2016-06-02 | Amgen Inc. | Vial adapter and system |
CA3021845C (en) | 2011-04-20 | 2022-03-29 | Amgen Inc. | Autoinjector apparatus |
DE102012016127A1 (en) | 2011-08-31 | 2013-02-28 | Daniel Elias | Error correction encoding apparatus for data stream, supplies one of m' mutually different synchronous words to each block in error correction information |
WO2013055958A1 (en) | 2011-10-11 | 2013-04-18 | Genentech, Inc. | Improved assembly of bispecific antibodies |
ES2675035T3 (en) | 2011-10-14 | 2018-07-05 | Amgen, Inc | Injector and assembly method |
EP2809684A1 (en) | 2012-01-31 | 2014-12-10 | Genentech, Inc. | Anti-ig-e m1' antibodies and methods using same |
CA2861124A1 (en) | 2012-02-10 | 2013-08-15 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
WO2013148117A1 (en) | 2012-03-27 | 2013-10-03 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
CN104395339A (en) | 2012-06-27 | 2015-03-04 | 弗·哈夫曼-拉罗切有限公司 | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
RU2015100656A (en) | 2012-06-27 | 2016-08-20 | Ф. Хоффманн-Ля Рош Аг | METHOD FOR PRODUCING ANTIBODY FC-FRAGMENT CONNECTING, INCLUDING AT LEAST ONE CONNECTING GROUP, WHICH SPECIALLY RELATED TO THE TARGET, AND THEIR APPLICATION |
JP2015535464A (en) | 2012-11-21 | 2015-12-14 | アムジエン・インコーポレーテツド | Drug delivery device |
JP6272907B2 (en) | 2013-01-30 | 2018-01-31 | エヌジーエム バイオファーマシューティカルズ インコーポレイテッド | Compositions and methods of use in the treatment of metabolic disorders |
US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
JOP20140087B1 (en) | 2013-03-13 | 2021-08-17 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
US10092703B2 (en) | 2013-03-15 | 2018-10-09 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
CA2904661C (en) | 2013-03-15 | 2022-03-15 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
JP6670740B2 (en) | 2013-03-22 | 2020-03-25 | アムジエン・インコーポレーテツド | Injector and assembly method |
US9765166B2 (en) | 2013-10-17 | 2017-09-19 | The Nippon Synthetic Chemical Industry Co., Ltd. | Crosslinkable polymer |
AU2014340174B2 (en) | 2013-10-24 | 2019-09-12 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
KR102458637B1 (en) | 2013-10-24 | 2022-10-24 | 암겐 인코포레이티드 | Injector and method of assembly |
WO2015119906A1 (en) | 2014-02-05 | 2015-08-13 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
EP3140392B1 (en) | 2014-05-06 | 2023-07-26 | F. Hoffmann-La Roche AG | Production of heteromultimeric proteins using mammalian cells |
JP6640113B2 (en) | 2014-05-07 | 2020-02-05 | アムジエン・インコーポレーテツド | Auto-injector with impact reducing element |
JP6822843B2 (en) | 2014-06-03 | 2021-01-27 | アムジエン・インコーポレーテツド | Systems and methods for remotely processing data collected by drug delivery devices |
MX370115B (en) | 2014-07-30 | 2019-12-02 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders. |
CA2957960C (en) | 2014-10-14 | 2023-08-22 | Amgen, Inc. | Drug injection device with visual and audible indicators |
MX357994B (en) | 2014-10-31 | 2018-08-01 | Ngm Biopharmaceuticals Inc | COMPOSITIONS and METHODS OF USE FOR TREATING METABOLIC DISORDERS. |
CN107001482B (en) | 2014-12-03 | 2021-06-15 | 豪夫迈·罗氏有限公司 | Multispecific antibodies |
WO2016100055A1 (en) | 2014-12-19 | 2016-06-23 | Amgen Inc. | Drug delivery device with live button or user interface field |
JP6716566B2 (en) | 2014-12-19 | 2020-07-01 | アムジエン・インコーポレーテツド | Drug delivery device with proximity sensor |
EP3258988B1 (en) | 2015-02-17 | 2019-08-28 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
ES2905870T3 (en) | 2015-02-27 | 2022-04-12 | Amgen Inc | Drug delivery device having a needle guard mechanism with an adjustable threshold resistance to movement of the needle guard |
HRP20231544T1 (en) | 2015-08-13 | 2024-03-15 | Amgen Inc. | Charged depth filtration of antigen-binding proteins |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
WO2017100501A1 (en) | 2015-12-09 | 2017-06-15 | Amgen Inc. | Auto-injector with signaling cap |
US11154661B2 (en) | 2016-01-06 | 2021-10-26 | Amgen Inc. | Auto-injector with signaling electronics |
WO2017160799A1 (en) | 2016-03-15 | 2017-09-21 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
JP7021099B2 (en) | 2016-03-31 | 2022-02-18 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | Bound protein and how to use it |
US11541168B2 (en) | 2016-04-29 | 2023-01-03 | Amgen Inc. | Drug delivery device with messaging label |
WO2017192287A1 (en) | 2016-05-02 | 2017-11-09 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
AU2017263558B2 (en) | 2016-05-13 | 2022-12-22 | Amgen Inc. | Vial sleeve assembly |
WO2017200989A1 (en) | 2016-05-16 | 2017-11-23 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
US11541176B2 (en) | 2016-06-03 | 2023-01-03 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
EP3478342A1 (en) | 2016-07-01 | 2019-05-08 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
WO2018034784A1 (en) | 2016-08-17 | 2018-02-22 | Amgen Inc. | Drug delivery device with placement detection |
EP3532127A1 (en) | 2016-10-25 | 2019-09-04 | Amgen Inc. | On-body injector |
MX2019008432A (en) | 2017-01-17 | 2019-11-18 | Amgen Inc | Injection devices and related methods of use and assembly. |
CA3048520A1 (en) | 2017-02-17 | 2018-08-23 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
AU2018221351B2 (en) | 2017-02-17 | 2023-02-23 | Amgen Inc. | Insertion mechanism for drug delivery device |
EP3592403A1 (en) | 2017-03-06 | 2020-01-15 | Amgen Inc. | Drug delivery device with activation prevention feature |
JP2020509839A (en) | 2017-03-07 | 2020-04-02 | アムジエン・インコーポレーテツド | Needle insertion due to overpressure |
KR20240005194A (en) | 2017-03-09 | 2024-01-11 | 암겐 인코포레이티드 | Insertion mechanism for drug delivery device |
KR102517342B1 (en) | 2017-03-28 | 2023-03-31 | 암겐 인코포레이티드 | Plunger rod and syringe assembly systems and methods |
CN111344304B (en) | 2017-06-01 | 2023-09-01 | Pb免疫治疗公司 | Novel anti-CD 40 antibodies and uses thereof |
EP3634539A1 (en) | 2017-06-08 | 2020-04-15 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
AU2018282077B2 (en) | 2017-06-08 | 2023-11-23 | Amgen Inc. | Torque driven drug delivery device |
MX2019015472A (en) | 2017-06-22 | 2020-02-19 | Amgen Inc | Device activation impact/shock reduction. |
MA49461A (en) | 2017-06-23 | 2020-04-29 | Amgen Inc | ELECTRONIC DRUG DELIVERY DEVICE INCLUDING A CAP ACTIVATED BY A SWITCH ASSEMBLY |
IL270784B2 (en) | 2017-07-14 | 2023-11-01 | Amgen Inc | Needle insertion-retraction system having dual torsion spring system |
IL271173B1 (en) | 2017-07-21 | 2023-12-01 | Amgen Inc | Gas permeable sealing member for drug container and methods of assembly |
WO2019022950A1 (en) | 2017-07-25 | 2019-01-31 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
EP3658203B1 (en) | 2017-07-25 | 2022-08-31 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
EP3664863A2 (en) | 2017-08-09 | 2020-06-17 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
US11077246B2 (en) | 2017-08-18 | 2021-08-03 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
EP3691717B1 (en) | 2017-10-04 | 2023-02-08 | Amgen Inc. | Flow adapter for drug delivery device |
WO2019070552A1 (en) | 2017-10-06 | 2019-04-11 | Amgen Inc. | Drug delivery device with interlock assembly and related method of assembly |
EP3694578A1 (en) | 2017-10-09 | 2020-08-19 | Amgen Inc. | Drug delivery device with drive assembly and related method of assembly |
MA50528A (en) | 2017-11-03 | 2020-09-09 | Amgen Inc | SYSTEMS AND APPROACHES TO STERILIZE A DRUG DELIVERY DEVICE |
EP3707075A1 (en) | 2017-11-06 | 2020-09-16 | Amgen Inc. | Fill-finish assemblies and related methods |
JP2021501616A (en) | 2017-11-06 | 2021-01-21 | アムジエン・インコーポレーテツド | Drug delivery device with placement and flow detection |
EP3706826A1 (en) | 2017-11-10 | 2020-09-16 | Amgen Inc. | Plungers for drug delivery devices |
WO2019099322A1 (en) | 2017-11-16 | 2019-05-23 | Amgen Inc. | Autoinjector with stall and end point detection |
MX2020004996A (en) | 2017-11-16 | 2020-08-27 | Amgen Inc | Door latch mechanism for drug delivery device. |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
WO2020023444A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
US20210260279A1 (en) | 2018-07-24 | 2021-08-26 | Amgen Inc. | Hybrid drug delivery devices with optional grip portion and related method of preparation |
CA3103682A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Delivery devices for administering drugs |
MA53320A (en) | 2018-07-31 | 2021-11-03 | Amgen Inc | FLUID PATH ASSEMBLY FOR DRUG DELIVERY DEVICE |
JP2022500095A (en) | 2018-09-24 | 2022-01-04 | アムジエン・インコーポレーテツド | Intervention dosing system and method |
AU2019350660A1 (en) | 2018-09-28 | 2021-03-18 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
JP2022503983A (en) | 2018-10-02 | 2022-01-12 | アムジエン・インコーポレーテツド | Injection system for drug delivery with internal force transmission |
CA3112214A1 (en) | 2018-10-05 | 2020-04-09 | Amgen Inc. | Drug delivery device having dose indicator |
WO2020081479A1 (en) | 2018-10-15 | 2020-04-23 | Amgen Inc. | Drug delivery device having damping mechanism |
EA202191038A1 (en) | 2018-10-15 | 2021-07-06 | Эмджен Инк. | METHOD OF PLATFORM ASSEMBLY FOR MEDICINE DELIVERY DEVICE |
US11213620B2 (en) | 2018-11-01 | 2022-01-04 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
US20220031953A1 (en) | 2018-11-01 | 2022-02-03 | Amgen Inc. | Drug delivery devices with partial needle retraction |
EP3873563A1 (en) | 2018-11-01 | 2021-09-08 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
MX2021012557A (en) | 2019-04-24 | 2021-11-12 | Amgen Inc | Syringe sterilization verification assemblies and methods. |
US20220273887A1 (en) | 2019-08-23 | 2022-09-01 | Amgen Inc. | Drug delivery device with configurable needle shield engagement components and related methods |
CA3217207A1 (en) | 2021-05-21 | 2022-11-24 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4710473A (en) | 1983-08-10 | 1987-12-01 | Amgen, Inc. | DNA plasmids |
US4496689A (en) * | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
JP2876058B2 (en) | 1986-08-18 | 1999-03-31 | エミスフィア・テクノロジーズ・インコーポレイテッド | Drug delivery system |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
EP0315456B1 (en) | 1987-11-05 | 1994-06-01 | Hybritech Incorporated | Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics |
US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
NZ241954A (en) | 1991-03-15 | 1994-01-26 | Amgen Inc | Compositions of g-csf for pulmonary administration. |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5733731A (en) | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
CA2118130A1 (en) | 1992-04-14 | 1993-10-28 | Jean M. J. Frechet | Dendritic based macromolecules and method of production |
US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
US5417972A (en) * | 1993-08-02 | 1995-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM |
US5470952A (en) | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
DE4435919C1 (en) | 1994-10-07 | 1995-12-07 | Deutsches Krebsforsch | DNA encoding zinc finger protein |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6127977A (en) | 1996-11-08 | 2000-10-03 | Cohen; Nathan | Microstrip patch antenna with fractal structure |
ATE279947T1 (en) | 1996-03-18 | 2004-11-15 | Univ Texas | IMMUNOGLOBULIN-LIKE DOMAIN WITH INCREASED HALF-LIFE TIMES |
AU4474497A (en) | 1996-10-08 | 1998-05-05 | U-Bisys B.V. | Methods and means for selecting peptides and proteins having specific affinity for a target |
US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
JP2001503263A (en) | 1996-10-25 | 2001-03-13 | ヒューマン ジノーム サイエンシーズ,インコーポレイテッド | Neutrokine α |
AU5705898A (en) | 1996-12-17 | 1998-07-15 | Schering Corporation | Mammalian cell surface antigens; related reagents |
US5969102A (en) | 1997-03-03 | 1999-10-19 | St. Jude Children's Research Hospital | Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof |
CA2232743A1 (en) | 1997-04-02 | 1998-10-02 | Smithkline Beecham Corporation | A tnf homologue, tl5 |
IL133315A0 (en) | 1997-06-06 | 2001-04-30 | Regeneron Pharma | Ntn-2 member of tnf ligand family |
WO1998055621A1 (en) | 1997-06-06 | 1998-12-10 | Regeneron Pharmaceuticals, Inc. | Ntn-2 member of tnf ligand family |
WO1999011791A2 (en) | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
EA200000311A1 (en) | 1997-09-12 | 2000-10-30 | Апотек Р Энд Д Са | NEW PROTEIN IMMUNE SYSTEM - KAU |
AU2212299A (en) | 1998-01-05 | 1999-07-26 | Genentech Inc. | Compositions and methods for the treatment of tumor |
WO1999062951A1 (en) * | 1998-06-04 | 1999-12-09 | Shanghai Second Medical University | A human zinc finger protein gene (bmzf3) |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
ATE453712T1 (en) | 1999-01-07 | 2010-01-15 | Zymogenetics Inc | METHOD FOR THERAPEUTIC USE OF SOLUBLE RECEPTORS BR43X2 |
US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
ES2204528T3 (en) | 1999-01-25 | 2004-05-01 | Biogen, Inc. | BAFF, ITS INHIBITORS AND THEIR USE IN THE MODULATION OF THE CELL RESPONSE B. |
WO2000047740A2 (en) | 1999-02-12 | 2000-08-17 | Amgen Inc. | Tnf-related proteins |
US20030022233A1 (en) | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
US6475987B1 (en) | 1999-05-06 | 2002-11-05 | National Jewish Medical And Research Center | Tall-1 receptor homologues |
CA2377731A1 (en) | 1999-07-02 | 2001-01-11 | Genentech, Inc. | Fusion peptides comprising a peptide ligand domain and a multimerization domain |
MXPA02007574A (en) | 2000-02-11 | 2002-12-13 | Amgen Inc | Receptor from tnf family. |
US20030091565A1 (en) | 2000-08-18 | 2003-05-15 | Beltzer James P. | Binding polypeptides and methods based thereon |
EP2261246A3 (en) | 2000-08-18 | 2011-07-13 | Human Genome Sciences, Inc. | Binding polypeptides for B-lymphocyte stimulator protein (BLyS) |
ATE549354T1 (en) * | 2001-05-11 | 2012-03-15 | Amgen Inc | PEPTIDES AND ASSOCIATED TALL-1 BINDING MOLECULES |
AR035119A1 (en) | 2001-08-16 | 2004-04-14 | Lilly Co Eli | ANTI-HTNFSF13B HUMAN ANTI-BODIES |
WO2004060911A2 (en) * | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
CA2572765C (en) * | 2004-07-08 | 2013-05-21 | Amgen Inc. | Compound having improved bioefficiency when administered in a multidose regimen |
US8008453B2 (en) * | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
WO2008069180A1 (en) | 2006-12-05 | 2008-06-12 | Kabushiki Kaisha Kobe Seiko Sho | High-strength aluminum alloy plate for printing plate |
US9458246B2 (en) * | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
JOP20140087B1 (en) * | 2013-03-13 | 2021-08-17 | Amgen Inc | Proteins specific for baff and b7rp1 and uses thereof |
-
2002
- 2002-05-13 AT AT10178373T patent/ATE549354T1/en active
- 2002-05-13 ES ES07019762.9T patent/ES2527471T3/en not_active Expired - Lifetime
- 2002-05-13 PL PL39331702A patent/PL393317A1/en unknown
- 2002-05-13 SK SK1489-2003A patent/SK288175B6/en not_active IP Right Cessation
- 2002-05-13 SI SI200230645T patent/SI1385882T1/en unknown
- 2002-05-13 AT AT02769739T patent/ATE375361T1/en active
- 2002-05-13 DE DE60222882T patent/DE60222882T2/en not_active Expired - Lifetime
- 2002-05-13 EA EA200301241A patent/EA010435B1/en not_active IP Right Cessation
- 2002-05-13 CN CNB028140095A patent/CN100448891C/en not_active Expired - Fee Related
- 2002-05-13 BR BR0209546-7A patent/BR0209546A/en not_active Application Discontinuation
- 2002-05-13 MX MXPA03010210A patent/MXPA03010210A/en active IP Right Grant
- 2002-05-13 ES ES10178373T patent/ES2387546T3/en not_active Expired - Lifetime
- 2002-05-13 EP EP20070019762 patent/EP1921088B1/en not_active Expired - Lifetime
- 2002-05-13 AU AU2002342669A patent/AU2002342669C1/en not_active Ceased
- 2002-05-13 NZ NZ542878A patent/NZ542878A/en not_active IP Right Cessation
- 2002-05-13 HU HU0700125A patent/HU229910B1/en not_active IP Right Cessation
- 2002-05-13 CZ CZ2003-3291A patent/CZ304592B6/en not_active IP Right Cessation
- 2002-05-13 EE EEP200300552A patent/EE05294B1/en not_active IP Right Cessation
- 2002-05-13 PL PL369570A patent/PL210546B1/en unknown
- 2002-05-13 DK DK02769739T patent/DK1385882T3/en active
- 2002-05-13 PT PT02769739T patent/PT1385882E/en unknown
- 2002-05-13 EP EP14180109.2A patent/EP2845864A3/en not_active Withdrawn
- 2002-05-13 EP EP20100178373 patent/EP2292655B1/en not_active Expired - Lifetime
- 2002-05-13 RS YU95203A patent/RS51708B/en unknown
- 2002-05-13 US US10/145,206 patent/US7259137B2/en not_active Expired - Lifetime
- 2002-05-13 CA CA2446189A patent/CA2446189C/en not_active Expired - Fee Related
- 2002-05-13 JP JP2002589503A patent/JP4516719B2/en not_active Expired - Lifetime
- 2002-05-13 CN CNA2006101537090A patent/CN1970077A/en active Pending
- 2002-05-13 IL IL15871902A patent/IL158719A0/en unknown
- 2002-05-13 KR KR1020037014672A patent/KR100902687B1/en active IP Right Grant
- 2002-05-13 EP EP02769739A patent/EP1385882B9/en not_active Expired - Lifetime
- 2002-05-13 NZ NZ529267A patent/NZ529267A/en not_active IP Right Cessation
- 2002-05-13 WO PCT/US2002/015273 patent/WO2002092620A2/en active IP Right Grant
- 2002-05-13 CN CNA2006101537137A patent/CN1970078A/en active Pending
- 2002-05-13 ES ES02769739T patent/ES2295404T3/en not_active Expired - Lifetime
-
2003
- 2003-10-31 ZA ZA200308513A patent/ZA200308513B/en unknown
- 2003-11-02 IL IL158719A patent/IL158719A/en not_active IP Right Cessation
- 2003-11-10 NO NO20034980A patent/NO331785B1/en not_active IP Right Cessation
- 2003-11-12 BG BG108349A patent/BG66270B1/en unknown
-
2004
- 2004-02-25 HK HK04101344A patent/HK1059269A1/en not_active IP Right Cessation
-
2005
- 2005-11-10 US US11/272,521 patent/US7737111B2/en not_active Expired - Fee Related
-
2008
- 2008-01-09 CY CY081100030T patent/CY1107131T1/en unknown
-
2010
- 2010-05-26 US US12/788,137 patent/US8507426B2/en not_active Expired - Fee Related
-
2011
- 2011-06-04 HK HK11105624A patent/HK1151545A1/en not_active IP Right Cessation
-
2013
- 2013-07-09 US US13/938,141 patent/US9139645B2/en not_active Expired - Fee Related
-
2015
- 2015-08-21 HK HK15108146.9A patent/HK1207390A1/en unknown
- 2015-09-21 US US14/860,381 patent/US20160176926A1/en not_active Abandoned
Non-Patent Citations (2)
Title |
---|
KHARE ET AL.: "Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenis mice", PROC. NATL. ACAD. SCI. USA, vol. 97, no. 7, 28 March 2000 (2000-03-28), pages 3370 - 3375, XP002142253 * |
SHU H.-B. ET AL.: "B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1", PROC. NATL. ACAD. SCI. USA, vol. 97, no. 16, 1 August 2000 (2000-08-01), pages 9156 - 9161, XP002160851 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7645861B2 (en) | 2004-09-24 | 2010-01-12 | Amgen Inc. | Modified Fc molecules |
US7655764B2 (en) | 2004-09-24 | 2010-02-02 | Amgen Inc. | Modified Fc molecules |
US7655765B2 (en) | 2004-09-24 | 2010-02-02 | Amgen Inc. | Modified Fc molecules |
US7662931B2 (en) | 2004-09-24 | 2010-02-16 | Amgen Inc. | Modified Fc molecules |
US7750128B2 (en) | 2004-09-24 | 2010-07-06 | Amgen Inc. | Modified Fc molecules |
US7750127B2 (en) | 2004-09-24 | 2010-07-06 | Amgen Inc. | Modified Fc molecules |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
US9114175B2 (en) | 2005-08-12 | 2015-08-25 | Amgen Inc. | Modified Fc molecules |
US9382323B2 (en) | 2009-04-02 | 2016-07-05 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002092620A3 (en) | Peptides and related molecules that bind to tall-1 | |
EP1666498A3 (en) | Soluble CTLA4 molecules, compositions comprising said molecules and uses thereof | |
BG107242A (en) | Modulator of the parathyroid hormone receptors and protein of parathyroid-related hormone | |
AU2348595A (en) | Preparation of bitumen/polymer compositions, and use thereof | |
AU2001290837A1 (en) | Use of a polypeptide comprising the extracellular domains of il-20rb for the treatment of inflammation | |
WO1999054459A8 (en) | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression | |
NO991786L (en) | Use of polymer dispersions as binder in compounds suitable for sealing and coating | |
WO2000042973A3 (en) | Homing pro-apoptotic conjugates and methods of using same | |
AU6276700A (en) | Liquid-crystalline medium | |
BR0011030A (en) | Compositions of substantially oil-free cycloporin | |
WO1999056705A3 (en) | Long wear nail polish having defined surface properties | |
WO2001081376A3 (en) | Apo-ai/aii peptide derivatives | |
DE602005025464D1 (en) | AMINO ACID AND PEPTIDE CONJUGATES OF ARYL ALKYLIC ACIDS FOR USE IN COSMETICS | |
ATE433458T1 (en) | SHIP-1 MODULATORS | |
WO2001083526A3 (en) | Calcitonin-related molecules | |
AU4263696A (en) | Peptides capable of binding to the gap protein sh3 domain, nucleotide sequences coding therefor, and preparation and use thereof | |
AU2001248822A1 (en) | Gd3-mimetic peptides | |
WO2001083518A3 (en) | Molecules that modulate ubiquitin-dependent proteolysis and methods for identifying same | |
DE60038955D1 (en) | LOCALIZED COLLIGIN / HsP47 AT THE SURFACE OF CARCINOMA CELLS | |
WO2001058954A3 (en) | Trade molecules and uses related thereto | |
AU2118500A (en) | Transcription factor e2f dna-binding domain inhibitor peptides and their use | |
Yu et al. | Learning from the Pieces: The Adhesion of Mussel-Inspired Peptides |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-952/03 Country of ref document: YU |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1-2003-501132 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2446189 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003/08513 Country of ref document: ZA Ref document number: 200308513 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 158719 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 529267 Country of ref document: NZ Ref document number: 2002342669 Country of ref document: AU Ref document number: 2002769739 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/010210 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002589503 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037014672 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 10834902 Country of ref document: BG Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2003-3291 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14892003 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200301241 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20028140095 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002769739 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-3291 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002342669 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002769739 Country of ref document: EP |